BRPI0905849A2 - Composto, composição farmacêutica e método - Google Patents

Composto, composição farmacêutica e método

Info

Publication number: BRPI0905849A2
Authority: BR; Brazil
Prior art keywords: disorders; mood; piperidine derivatives; substituted spirocyclic; disease
Prior art date: 2008-01-30

Application number

BRPI0905849-4A

Other languages

English (en)

Inventor

Reddeppareddy Dandu

Robert L Hudkins

Babu G Sundar

Original Assignee

Cephalon Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-01-30

Filing date

2009-01-28

Publication date

2015-06-30

2009-01-28 Application filed by Cephalon Inc filed Critical Cephalon Inc

2015-06-30 Publication of BRPI0905849A2 publication Critical patent/BRPI0905849A2/pt

Links

150000001875 compounds Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
208000035475 disorder Diseases 0.000 abstract 3
208000024827 Alzheimer disease Diseases 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
150000003053 piperidines Chemical class 0.000 abstract 2
208000020016 psychiatric disease Diseases 0.000 abstract 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
102000004384 Histamine H3 receptors Human genes 0.000 abstract 1
108090000981 Histamine H3 receptors Proteins 0.000 abstract 1
206010061218 Inflammation Diseases 0.000 abstract 1
208000026139 Memory disease Diseases 0.000 abstract 1
208000019695 Migraine disease Diseases 0.000 abstract 1
208000019022 Mood disease Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000002193 Pain Diseases 0.000 abstract 1
230000004075 alteration Effects 0.000 abstract 1
230000037007 arousal Effects 0.000 abstract 1
208000010877 cognitive disease Diseases 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
206010015037 epilepsy Diseases 0.000 abstract 1
230000004634 feeding behavior Effects 0.000 abstract 1
230000004054 inflammatory process Effects 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
206010027599 migraine Diseases 0.000 abstract 1
230000036651 mood Effects 0.000 abstract 1
201000003152 motion sickness Diseases 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
201000003631 narcolepsy Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
208000023504 respiratory system disease Diseases 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Hydrogenated Pyridines (AREA)

BRPI0905849-4A 2008-01-30 2009-01-28 Composto, composição farmacêutica e método BRPI0905849A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6290908P	2008-01-30	2008-01-30
PCT/US2009/032195 WO2009097309A1 (en)	2008-01-30	2009-01-28	Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands

Publications (1)

Publication Number	Publication Date
BRPI0905849A2 true BRPI0905849A2 (pt)	2015-06-30

Family

ID=40445314

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0905849-4A BRPI0905849A2 (pt)	2008-01-30	2009-01-28	Composto, composição farmacêutica e método

Country Status (18)

Country	Link
US (2)	US8524713B2 (pt)
EP (1)	EP2257553B1 (pt)
JP (1)	JP5524082B2 (pt)
KR (1)	KR20100105789A (pt)
CN (1)	CN101932585B (pt)
AT (1)	ATE522538T1 (pt)
AU (1)	AU2009209235B2 (pt)
BR (1)	BRPI0905849A2 (pt)
CA (1)	CA2712888A1 (pt)
EA (1)	EA018537B1 (pt)
ES (1)	ES2370378T3 (pt)
IL (1)	IL206914A (pt)
MX (1)	MX2010008382A (pt)
MY (1)	MY150062A (pt)
NZ (1)	NZ587034A (pt)
UA (1)	UA100877C2 (pt)
WO (1)	WO2009097309A1 (pt)
ZA (1)	ZA201005136B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20130044T1 (hr)	2006-07-25	2013-02-28	Cephalon, Inc.	Derivati piridizinona
EP2752406A1 (en)	2008-01-30	2014-07-09	Cephalon, Inc.	Substituted pyridazine derivatives which have histamine H3 antagonist activity
WO2009142732A2 (en) *	2008-05-20	2009-11-26	Cephalon, Inc.	Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
CN102099036B (zh)	2008-06-03	2015-05-27	英特芒尼公司	用于治疗炎性疾患和纤维化疾患的化合物和方法
TWI522361B (zh)	2010-07-09	2016-02-21	艾伯維公司	作為s1p調節劑的稠合雜環衍生物
TW201643169A (zh)	2010-07-09	2016-12-16	艾伯維股份有限公司	作為s1p調節劑的螺-哌啶衍生物
TW201206893A (en)	2010-07-09	2012-02-16	Abbott Healthcare Products Bv	Bisaryl (thio) morpholine derivatives as S1P modulators
WO2012077655A1 (ja) *	2010-12-07	2012-06-14	塩野義製薬株式会社	Ｇｐｒ１１９アゴニスト活性を有するスピロ誘導体
ES2547916T3 (es)	2011-02-18	2015-10-09	Novartis Pharma Ag	Terapia de combinación de inhibidores de mTOR/JAK
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
MX382781B (es)	2014-04-02	2025-03-13	Intermune Inc	Piridinonas anti-fibroticas.
JP6643764B2 (ja) *	2016-02-05	2020-02-12	国立大学法人岐阜大学	抗がん剤
EP3684364A4 (en)	2017-09-18	2021-06-02	Goldfinch Bio, Inc.	PYRIDAZINONE AND METHOD OF USE THEREOF
US11535632B2 (en)	2019-10-31	2022-12-27	ESCAPE Bio, Inc.	Solid forms of an S1P-receptor modulator

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0313762D0 (en) *	2003-06-13	2003-07-23	Biofocus Plc	Compound libraries
NZ546834A (en) *	2003-10-01	2010-03-26	Adolor Corp	Spirocyclic heterocyclic derivatives and methods of their use
SE0403160D0 (sv) *	2004-12-23	2004-12-23	Biovitrum Ab	New compounds
ES2381205T3 (es) *	2005-11-10	2012-05-24	Msd K.K.	Derivado espiro aza-sustituido
WO2007063385A2 (en) *	2005-12-01	2007-06-07	Pfizer Products Inc.	Spirocyclic amine histamine-3 receptor antagonists
WO2007088462A1 (en) *	2006-02-01	2007-08-09	Pfizer Products Inc.	Spirochromane antagonists of the h-3 receptor

2009
- 2009-01-28 UA UAA201010456A patent/UA100877C2/ru unknown
- 2009-01-28 ES ES09706445T patent/ES2370378T3/es active Active
- 2009-01-28 AT AT09706445T patent/ATE522538T1/de not_active IP Right Cessation
- 2009-01-28 BR BRPI0905849-4A patent/BRPI0905849A2/pt not_active IP Right Cessation
- 2009-01-28 KR KR1020107019040A patent/KR20100105789A/ko not_active Ceased
- 2009-01-28 AU AU2009209235A patent/AU2009209235B2/en not_active Ceased
- 2009-01-28 MY MYPI2010003298A patent/MY150062A/en unknown
- 2009-01-28 EP EP09706445A patent/EP2257553B1/en not_active Not-in-force
- 2009-01-28 CN CN2009801037142A patent/CN101932585B/zh not_active Expired - Fee Related
- 2009-01-28 JP JP2010545098A patent/JP5524082B2/ja not_active Expired - Fee Related
- 2009-01-28 NZ NZ587034A patent/NZ587034A/en not_active IP Right Cessation
- 2009-01-28 EA EA201070903A patent/EA018537B1/ru not_active IP Right Cessation
- 2009-01-28 MX MX2010008382A patent/MX2010008382A/es active IP Right Grant
- 2009-01-28 CA CA2712888A patent/CA2712888A1/en not_active Abandoned
- 2009-01-28 WO PCT/US2009/032195 patent/WO2009097309A1/en not_active Ceased
2010
- 2010-07-08 IL IL206914A patent/IL206914A/en not_active IP Right Cessation
- 2010-07-19 ZA ZA2010/05136A patent/ZA201005136B/en unknown
- 2010-07-29 US US12/846,108 patent/US8524713B2/en active Active
2013
- 2013-07-24 US US13/949,323 patent/US20130310389A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20100298332A1 (en)	2010-11-25
EP2257553B1 (en)	2011-08-31
MY150062A (en)	2013-11-29
CN101932585B (zh)	2013-07-10
IL206914A0 (en)	2010-12-30
ZA201005136B (en)	2013-12-23
HK1151526A1 (en)	2012-02-03
WO2009097309A1 (en)	2009-08-06
AU2009209235A1 (en)	2009-08-06
ES2370378T3 (es)	2011-12-14
IL206914A (en)	2013-03-24
EA201070903A1 (ru)	2011-02-28
MX2010008382A (es)	2010-11-25
US8524713B2 (en)	2013-09-03
ATE522538T1 (de)	2011-09-15
UA100877C2 (ru)	2013-02-11
KR20100105789A (ko)	2010-09-29
NZ587034A (en)	2011-12-22
AU2009209235B2 (en)	2013-07-18
EP2257553A1 (en)	2010-12-08
US20130310389A1 (en)	2013-11-21
EA018537B1 (ru)	2013-08-30
CN101932585A (zh)	2010-12-29
CA2712888A1 (en)	2009-08-06
JP2011510992A (ja)	2011-04-07
JP5524082B2 (ja)	2014-06-18

Legal Events

Date	Code	Title	Description
2016-11-29	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-03-14	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2395 DE 29-11-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0905849A2 (pt)	2015-06-30	Composto, composição farmacêutica e método
BRPI0811842A2 (pt)	2014-11-18	Composto, composição farmacêutica, uso de um composto, e, métodos para aumentar a qualidade do sono em um paciente mamífero, para tratar a insônia em um paciente mamífero, e para tratar ou controlar a obesidade em um paciente mamífero
TN2011000209A1 (en)	2012-12-17	Aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
BRPI0408910A (pt)	2006-03-21	composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica
EP2282795A4 (en)	2016-01-06	TREATMENT OF RESPIRATORY DISEASES
CY1108230T1 (el)	2014-02-12	Παραγωγα 2-(1η-ινδολυλοσουλφανυλ)-βενζυλαμινης ως ssri
TN2012000231A1 (en)	2013-12-12	Quinoline amide m1 receptor positive allosteric modulators
BR112012011105A2 (pt)	2019-09-24	derivados de oxazolina para tratamento de doenças do snc
WO2005079802A8 (en)	2006-11-09	Bipyridyl amides as modulators of metabotropic glutamate receptor-5
TR201819564T4 (tr)	2019-01-21	Cmt ve ilgili bozuklukların tedavisi için yeni terapötik yaklaşımlar.
CO6321133A2 (es)	2011-09-20	Nuevas 2-aminooxazolinas como ligandos taar1 para trastornos cns
BR112012003464B8 (pt)	2021-05-25	compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
EA201170352A1 (ru)	2011-08-30	Способы лечения расстройств цнс
NO20081434L (no)	2008-05-19	5-(fenylisoksazolyletoksy)-triazol-3-yl substituert pyridinsammensetninger for behandling av neurologisk, psykiatrisk eller smerteforstyrrelser
TW200833685A (en)	2008-08-16	Aminomethyl-4-imidazoles
EP2582676A4 (en)	2013-12-25	POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS
ECSP11010782A (es)	2011-02-28	Derivados de 4,5-dihidro-oxazol-2-ilo
CY1111429T1 (el)	2015-08-05	1,3-διυποκατεστημενα αμιδια 4-μεθυλο-1η-πυρρολο-2-καρβονικου οξεος και η χρησιμοποιηση τους για την παρασκευη φαρμακων
CY1109569T1 (el)	2014-08-13	Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης
ATE457985T1 (de)	2010-03-15	Substituierte pyrazinonderivate zur verwendung als arzneimittel
ATE552257T1 (de)	2012-04-15	Positive allosterische chinolizidinon-m1- rezeptormodulatoren
UA113776C2 (xx)	2017-03-10	Похідні піразолкарбоксаміду як модулятори рецепторів слідових амінів (taar) для застосування при лікуванні різних розладів, таких як депресія, діабет та хвороба паркінсона
BR112013010558A2 (pt)	2016-08-02	derivados de di-hidro-oxazol-2-amina
ATE513548T1 (de)	2011-07-15	Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy-)pyridi - 2-carboxamid zur behandlung motorischer störungen aufgrund der parkinsonschen krankheit
EA201171368A1 (ru)	2012-04-30	Новые гетероциклические соединения